Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Plos One|September 9, 2017
Meibomian gland features in a Norwegian cohort of patients with primary Sjögren´s syndromeXiangjun Chen, Øygunn Aass Utheim, Jiaxin Xiao, et al.
Journal of Refractive Surgery (Thorofare, N.J. : 1995)|June 10, 2022
Heidelberg Anterion Swept-Source OCT Corneal Epithelial Thickness Mapping: Repeatability and Agreement With Optovue AvantiYue Feng, Dan Z Reinstein, Tore Nitter, et al.
Current Eye Research|September 6, 2018
Tear Production Levels and Dry Eye Disease Severity in a Large Norwegian CohortMazyar Yazdani, Xiangjun Chen, Behzod Tashbayev, et al.
The Ocular Surface|November 27, 2020
Sex and age differences in symptoms and signs of dry eye disease in a Norwegian cohort of patientsSara Tellefsen Nøland, Reza A Badian, Tor P Utheim, et al.
Current Eye Research|April 9, 2019
Evaluation of the Ocular Surface Disease Index Questionnaire as a Discriminative Test for Clinical Findings in Dry Eye Disease PatientsMazyar Yazdani, Xiangjun Chen, Behzod Tashbayev, et al.
Experimental Hematology|December 13, 2005
Hematopoietic stem cells expanded by fibroblast growth factor-1 are excellent targets for retrovirus-mediated gene deliveryAleksandra Crcareva, Toshiki Saito, Atsushi Kunisato, et al.
The Journal of Biological Chemistry|April 29, 2015
The Crystal Structure of Cancer Osaka Thyroid Kinase Reveals an Unexpected Kinase Domain FoldSascha Gutmann, Alexandra Hinniger, Gabriele Fendrich, et al.
Journal of Medicinal Chemistry|August 10, 2016
Discovery of Imidazoquinolines as a Novel Class of Potent, Selective, and in Vivo Efficacious Cancer Osaka Thyroid (COT) Kinase InhibitorsRalf Glatthar, Aleksandar Stojanovic, Thomas Troxler, et al.
Haematologica|April 19, 2012
High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients--final analysis of a randomized, multicenter, phase III trialAndreas L Petzer, Dominic Fong, Thomas Lion, et al.
Haematologica|February 11, 2010
High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" studyAndreas L Petzer, Dominik Wolf, Dominic Fong, et al.
Pageof 7